A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

This observational study follows patients with relapsed or refractory follicular lymphoma — a slow-growing blood cancer — who have received a commercially available CAR-T cell therapy called lisocabtagene maraleucel (liso-cel) outside of a clinical trial. The goal is to collect real-world data on outcomes and safety. **You may be eligible if...** - You have been treated with the CAR-T therapy liso-cel for follicular lymphoma (Grade 1, 2, or 3a) in a real-world, post-approval setting in the United States **You may NOT be eligible if...** - You were treated with liso-cel as part of another clinical trial - You were treated for Grade 3b follicular lymphoma (a more aggressive subtype) - You received a non-standard or non-conforming version of the CAR-T product Talk to your doctor to see if this trial is right for you.